POPULARITY
Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167Articles discussed in this podcast episode include:Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloClaudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloRelacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo#asco2025Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, and Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167Articles discussed in this podcast episode include:Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlwClaudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlwRelacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlw#asco2025Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
La 61e édition du congrès de l'American Society of Clinical Oncology (ASCO) a réuni la semaine dernière à Chicago des milliers de spécialistes. Ce rendez-vous incontournable a mis en lumière les dernières avancées dans la lutte contre le cancer. Pour en discuter, nous recevons Alexandra Leary, oncologue spécialisée dans les cancers gynécologique et Jean-Emmanuel Bibault, médecin-chercheur spécialisé en oncologie et auteur de "Cancer Confidential" (Les Équateurs, 2025).
In today's episode, we sat down for part 2 of our discussion with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026-2027 president-elect of the American Society of Clinical Oncology (ASCO). Dr Mittendorf holds numerous leadership roles, including the Robert and Karen Hale Distinguished Chair in Surgical Oncology and vice chair for research in the Department of Surgery at Brigham and Women's Hospital; co-leader of the Breast Program and director of the Breast Immuno-Oncology Program at the Dana-Farber Brigham Cancer Center; co-leader of the Parker Institute for Cancer Immunotherapy at the Dana-Farber Cancer Institute; and a professor of surgery at Harvard Medical School, all in Boston, Massachusetts. In this discussion, Dr Mittendorf shared how ASCO is strategically preparing to address the long-term implications of proposed federal research funding cuts. She emphasized the significant return on investment generated by sustained NIH support, underscoring its role in fostering scientific innovation and stimulating the broader economy. She also advocated for structural reforms to be developed collaboratively with researchers, institutions, and policymakers to ensure continued progress in oncology is maintained, particularly in underfunded areas, such as prevention research. Dr Mittendorf also previewed her broader vision for ASCO, including expanding global collaboration and advancing equitable access to cancer care. She noted that these efforts will be complemented by continued emphasis on multidisciplinary care delivery and mentorship, which she discussed in more detail in part one of our conversation.
This year, Michael and Josh bring you the American Society of Clinical Oncology (ASCO) 2025. To keep it fresh, we're doing things a little differently, but rest assured, we'll bring along a global host of experts to deliver the very best from the practice-changing, thought-provoking, design-defining trials you know and love from this podcast.This episode focuses on adjuvant atezolizumab in the colon cancer space and the use of perioperative durvalumab in the gastric cancer space. Both are exciting spaces and have the potential to be practice-changing.Don't forget to like and subscribe if you love what we do!Studies discussed in the episode:ATOMICMATTERHORNFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Samira, a breast cancer survivor and CEO of Manta Cares, discusses the latest advancements in cancer treatment with Dr. Doug Blayney at the ASCO conference. They explore the significant impact of exercise on cancer treatment tolerance and survival, the de-escalation of chemotherapy, the introduction of new therapies like SERDs and antibody drug conjugates, and the role of circulating tumor DNA in monitoring cancer recurrence. The conversation emphasizes the importance of patient convenience and self-advocacy in cancer care.About Our Guest:Douglas W. Blayney, MD is a Professor of Medicine (Oncology), Emeritus, former Medical Director of Stanford Cancer Center, and specializes in the treatment of breast cancer. He has a special interest in the quality and value of cancer care. Dr. Blayney is a past president of the American Society of Clinical Oncology (ASCO), a founder of the ASCO Quality Symposium, a co-author of the ASCO value framework descriptions, and instigated the ASCO clinical "big data" effort, which is now CancerLinQ. He received the inaugural Ellen Stovall Award for Leadership in Patient Centered Care from the National Coalition for Cancer Survivorship in 2016. He was previously a Professor of Internal Medicine and Medical Director of the Comprehensive Cancer Center at the University of Michigan, and prior to that practiced and led Wilshire Oncology Medical Group, Inc. a physician owned multidisciplinary oncology practice in southern California. He has expertise on clinical trial development, use of oncology drugs in clinical practice, reimbursement and marketing strategies and information technology use.Chapter Codes00:00 The Impact of Exercise on Cancer Treatment02:00 Interview at ASCO Starts06:00 Advancements in Cancer Treatment: De-escalation and AI11:52 Emerging Therapies: SERDs and Antibody Drug Conjugates18:11 Circulating Tumor DNA: A New Frontier in Monitoring24:01 Convenience in Cancer Care: A Patient-Centric ApproachTakeaways- Regular exercise can increase tolerance to cancer treatments.- Data shows exercise has tangible benefits on survival rates.- De-escalation of chemotherapy is a key focus in cancer treatment.- AI is being integrated into cancer treatment guidelines.- Patients can take proactive steps to improve their health.- Oral SIRDs are emerging as a more convenient treatment option.- Antibody drug conjugates target cancer cells with fewer side effects.- Circulating tumor DNA can help detect cancer recurrence earlier.- Convenience in treatment is becoming a priority for patients.- Competition among treatments may help reduce costs for patients.Tags & Keywords:cancer treatment, ASCO, exercise, AI, SIRDs, antibody drug conjugates, circulating tumor DNA, patient care, chemotherapy, cancer survival, health technologyConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Listen Elsewhere: Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrwerIVhyJw67salKT-r9Qb_gadBvbHie YouTube: https://youtu.be/UjsAtpbedA8 Spotify: https://open.spotify.com/episode/7HwhjXHZU0ZWWVkXrCSV7V?si=d5e986f0885a4bbb Apple: https://podcasts.apple.com/us/podcast/cervical-cancer-and-hpv-what-you-need-to-know/id1622669098?i=1000710235401 Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Une étude publiée cette semaine dans le New England Journal of Medicine pourrait changer le traitement du cancer. Pour la première fois, il existe des preuves claires que l'exercice physique est encore plus efficace pour prévenir la récidive du cancer et la mort que de nombreux médicaments. Les résultats ont été présentés à Chicago lors de la réunion annuelle de l'American Society of Clinical Oncology (Asco). Notre invité revient tout juste de la conférence. Entrevue avec Dr. Normand Blais, hématologue et oncologue au CHUM. Regardez aussi cette discussion en vidéo via https://www.qub.ca/videos ou en vous abonnant à QUB télé : https://www.tvaplus.ca/qub ou sur la chaîne YouTube QUB https://www.youtube.com/@qub_radioPour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr
Une étude publiée cette semaine dans le New England Journal of Medicine pourrait changer le traitement du cancer. Pour la première fois, il existe des preuves claires que l'exercice physique est encore plus efficace pour prévenir la récidive du cancer et la mort que de nombreux médicaments. Les résultats ont été présentés à Chicago lors de la réunion annuelle de l'American Society of Clinical Oncology (Asco). Notre invité revient tout juste de la conférence. Entrevue avec Dr. Normand Blais, hématologue et oncologue au CHUM. Regardez aussi cette discussion en vidéo via https://www.qub.ca/videos ou en vous abonnant à QUB télé : https://www.tvaplus.ca/qub ou sur la chaîne YouTube QUB https://www.youtube.com/@qub_radioPour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr
Dealmaking by a pair of pharmas has given the biotech industry its best day of transactions in months, tallying nearly $13 billion in guaranteed payments across two deals. On the latest BioCentury This Week podcast, BioCentury's analysts discuss how the takeout of Blueprint Medicines for $9.1 billion up front gives Sanofi a drug for a rare immunological disorder and bolsters the French pharma's already strong presence in immunology. The analysts also assess the $3.5 billion partnership between BioNTech and Bristol Myers Squibb for an asset targeting cancer's hottest target, PD-(L)1 x VEGF, and underwhelming data from the leading asset against the target, PD-1 x VEGF bispecific ivonescimab, from Summit and Akeso Inc. Those data coincided with the kick-off of the American Society of Clinical Oncology (ASCO) meeting in Chicago, where almost a dozen companies were presenting readouts for another hot target, CLDN18.2. Evopoint is among the companies; its program recently attracted Astellas as a partner. Meanwhile, the biopharma industry is racing to counter the White House's most favored nation drug pricing strategy. BioCentury's Washington analyst, Steve Usdin, explains the urgency and details some of industry's options.View full story: https://www.biocentury.com/article/656097#biotech #biopharma #pharma #lifescience #deals00:00 - Introduction04:39 - Sanofi Buys Blueprint09:22 - BMS-BioNTech20:01 - Hot Targets23:40 - Drug PricingTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Lo studio italiano CASSANDRA di fase 3, randomizzato, multicentrico, appena presentato al Congresso annuale dell’American Society of Clinical Oncology (ASCO), a Chicago, e totalmente finanziato da associazioni di pazienti, ha coinvolto 17 ospedali in Italia, focalizzandosi sul trattamento preoperatorio dei pazienti con tumore del pancreas non metastatico, e ottenendo un miglioramento dei risultati rispetto all’attuale standard terapeutico. A Obiettivo Salute il commento del prof. Michele Reni, primario delle Unità Operative di Oncologia e Day Hospital Oncologico, direttore del programma strategico di coordinamento clinico del Pancreas Center all'IRCCS Ospedale San Raffaele, associato di Oncologia dell’Università Vita-Salute San Raffaele, ideatore e coordinatore dello studio.
In this episode, CancerNetwork® spoke with Eric Winer, MD, director of the Yale Cancer Center; president and physician-in-chief at Smilow Cancer Hospital; deputy dean for cancer research, Alfred Gilman Professor of Pharmacology, and Professor of Medicine at Yale School of Medicine; and chair of the association board for the American Society of Clinical Oncology (ASCO), about the current state of oncologist burnout, steps that can be taken to ameliorate it, and how it currently impacts professionals in the field. Causes of workplace burnout that authors identified in a paper published in the Journal of Clinical Oncology in January 2025 included the use of electronic health records, staffing levels, payer authorizations, hours worked, and age. Additionally, published results from the survey revealed a 14% increase in the rate of oncologists who experienced workplace burnout from 2013 to 2023 (P
Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, joins Gavin Cleaver to discuss what's being published at this year's American Society of Clinical Oncology (ASCO) meeting, what she's excited to see at the conference, and why ASCO is so important to the field.Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
As far as healthcare conferences go, the American Society of Clinical Oncology (ASCO) annual meeting is the top of the crop.Every year, thousands descend on Chicago for days worth of oncology-focused presentations, data readouts and industry-shaping news. Ahead of ASCO this weekend, Eisai's Dr. Corina Dutcus speaks with Pharma Editor Lecia Bushak to preview the annual oncology megaconference.Additionally, we dive into some data from the upcoming 2025 MM+M Agency 100 list, namely the representation of women at the C-suite level of leading medical marketing agencies. Also, don't forget to register to attend the 2025 Women of Distinction event on June 3 in New York. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
Kara Kenan is the founder & CEO of the Cancer Wellness Institute, where she trains and certifies cancer coaches globally. A passionate advocate for cancer survivorship, Kara has developed evidence-based programs that empower patients, survivors, and health professionals. She also serves as the Executive Director for Going Beyond the Pink, a North Carolina-based breast cancer support nonprofit, and Marketing & Communications Manager at the National Coalition for Cancer Survivorship (NCCS). Kara is actively involved in cancer policy and advocacy with NCCS and the Society for Integrative Oncology, and has been a treatment guideline reviewer with American Society for Clinical Oncology (ASCO). Leveraging AI, she has scaled her online courses, enhancing accessibility and support for cancer coaches worldwide. With over a decade of experience in coaching, advocacy, and curriculum development, Kara is dedicated to bridging gaps in survivorship care through education, innovation, and policy work.
Dr. Tania Small joined Bristol Myers Squibb as Senior Vice President, Global Medical Affairs in January 2024. Tania brings a strong scientific track record leading Medical Affairs teams in driving innovation that improves the experience and supports better outcomes of people living with cancer and rare diseases. She has successfully built and led global and regional medical organizations in Drug Development and Medical Affairs, advancing access to Oncology, Rare Disease and Hematology patients globally.Tania is a board-certified pediatric hematology, oncology, and bone marrow transplant specialist with deep experience in clinical research and drug development. She has extensive research experience in oncology, hematology, gene therapy and stem cell transplantation, receiving NIH grants for her translational research in gene therapy and regenerative medicine.Most recently, Tania served as Head of Global Medical Oncology and was the sponsor of the Global R&D Inclusion Diversity Council at GSK. Prior to GSK, Tania worked for IPSEN as Vice President, Head of Oncology and Rare Disease Global Drug Development.She is energized by revolutionizing the experience and outcomes for people with cancer, and has worked closely with the US FDA, Congress, and the American Society of Clinical Oncology (ASCO) to improve the diversity of enrollment in oncology clinical trials and elderly programs."I'm passionate about partnering to create programs that treat the person - not just the disease. Producing groundbreaking solutions that can change the trajectory of serious diseases and help write the next chapter of patient-driven science is what motivates me every day."Tania received her medical degree from Albert Einstein College of Medicine. She has a long-standing affiliation with the Morgan Stanley Children's Hospital of New York Presbyterian/Columbia University where she completed her residency and hematology/oncology fellowship with an academic research appointment in heme and bone marrow transplant.Currently, Tania serves on the ASCO Membership Advisory Committee and is a Board Member of Accreditation Council for Medical Affairs (ACMA).
Oncologist burnout and career dissatisfaction are a “huge problem,” says Robin T. Zon, MD, president of the American Society of Clinical Oncology (ASCO). Dr. Zon sits down with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, to discuss revelations from a recent ASCO report. “ASCO recognizes that if, in fact, we are going to accomplish our mission, we have to pay very close attention to what is happening to the workforce and the burnout that is associated with that,” Dr. Zon explains. She shares insights into common underlying causes and lays out a plan of attack for improvement. With an emphasis primarily on organizational, and not individual, reforms, Dr. Zon pledges that ASCO will remain focused on burnout and job dissatisfaction. “We are going to continue to have interventions. And we will continue to give voice to our members at all levels.” Dr. Zon reported various financial relationships. Dr. Figlin reported various financial relationships.
Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.
Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.
In this episode, Ayesha spoke with Mario Marcondes, MD, PhD, VP Head of Clinical Development at Nektar Therapeutics, a company focused on the discovery and development of novel therapies for autoimmune disorders and cancer. Dr. Marcondes is a licensed and trained physician, specializing in oncology and immune oncology. He has more than 15 years of research and teaching experience in Bone Marrow Transplant (BMT)/Cellular Therapies and more than 10 years of industry experience. He was the Program Lead for early-stage assets at Nektar and manages clinical trial programs from Phase I through to Phase III. Dr. Marcondes is a member of multiple professional clinical and translational research organizations, including the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), American Association for Cancer Research (AACR) and Center for International Blood & Marrow Transplant Research (CIBMTR). Listen to the episode to hear about the current research landscape in autoimmune disorders, including the work Dr. Marcondes is leading at Nektar Therapeutics. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
In this enlightening episode of The Patient From Hell podcast, Dr. Doug Blayney and host Samira Daswani dive deep into the key insights from the 2024 San Antonio Breast Cancer Symposium (SABCS). They explore four critical areas of breast cancer care: CDK4/6 inhibitors, antibody-drug conjugates (ADCs), de-escalation strategies for ductal carcinoma in situ (DCIS), and the emerging role of artificial intelligence in cancer diagnostics. Throughout the conversation, a central theme emerges: the increasing ability to personalize cancer treatment, considering individual patient characteristics, biological markers, treatment options, and personal goals for quality and quantity of life. Key Highlights: 1. Biomarkers are becoming increasingly sophisticated, allowing for more precise and personalized treatment approaches across different breast cancer subtypes. 2. Patient choice and individual considerations are paramount, with treatment decisions now focusing on balancing potential survival benefits against quality of life impacts. 3. Emerging technologies like antibody-drug conjugates and artificial intelligence are revolutionizing breast cancer care by offering more nuanced, targeted diagnostic and treatment options. About our guest: Dr. Doug Blayney is an oncology physician who specializes in breast cancer and the Chief Medical Officer of Manta Cares. His research focuses on quality improvement in cancer care systems, new drug development, and patient experience improvement. At the American Society of Clinical Oncology (ASCO), he was founding Editor-in-Chief of its flagship practice journal, and as President, started the ASCO Quality Symposium and began planning for ASCO's CancerLinq. He was a founding member of the National Comprehensive Cancer Network (NCCN) Growth Factor Guideline panel, and is a past member of the U.S. Food and Drug Administration's Oncology Drugs Advisory Committee and the NCCN Board of Directors. Key Moments: At 38 minutes: "There's a company now that has a gene expression panel that may predict, and it looks like it does predict, whether radiation treatment after standard treatment for DCIS is beneficial. So if this predicted biomarker of benefit for radiation pans out, and I think it probably will, that means that we can deescalate or personalize whether radiation treatment and its side effects are likely to be beneficial to that patient." At 45 minutes: "Quality of life, can that be answered by a nine question questionnaire? Well, maybe. If you can't get out of bed, your quality of life is because something hurts or if your arm doesn't work because they're so swollen, that's one extreme... What about 15 years playing that duet? What about three? It's those kind of subtleties that we need to take into account." At 49 minutes:"AI can interpret mammograms. The images from a mammogram 20 years ago, there were four, top, bottom, side, side, and maybe another oblique. And now there's 60 images from a mammogram. So that means that a radiologist, a human radiologist, whether it's next door or around the world, somebody needs to look at those. AI can help." Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
- Overview of ASCO's 2024 Theme – “The Art and Science of Cancer Care from Comfort to Cure” - Specific Updates on the Treatment of Colorectal Cancer Presented at ASCO - Quality-of-Life Issues: Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Specific Updates on the Treatment of Pancreas Cancer Presented at ASCO - The Role of Supportive Care - Specific Updates on the Treatment of Lymphoma Presented at ASCO - The Important Role of Clinical Trials: How Research Increases Treatment Options - Specific Updates on the Treatment of Leukemia Presented at ASCO - Communicating with Your Health Care Team: Key Questions to Ask - Specific Updates on the Treatment of Melanoma Presented at ASCO - Concluding Wrap-Up of Part II
- Overview of ASCO's 2024 Theme – “The Art and Science of Cancer Care from Comfort to Cure” - Specific Updates on the Treatment of Colorectal Cancer Presented at ASCO - Quality-of-Life Issues: Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Specific Updates on the Treatment of Pancreas Cancer Presented at ASCO - The Role of Supportive Care - Specific Updates on the Treatment of Lymphoma Presented at ASCO - The Important Role of Clinical Trials: How Research Increases Treatment Options - Specific Updates on the Treatment of Leukemia Presented at ASCO - Communicating with Your Health Care Team: Key Questions to Ask - Specific Updates on the Treatment of Melanoma Presented at ASCO - Concluding Wrap-Up of Part II
- Overview of ASCO's 2024 Theme – “The Art and Science of Cancer Care from Comfort to Cure” - Specific Updates on the Treatment of Colorectal Cancer Presented at ASCO - Quality-of-Life Issues: Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Specific Updates on the Treatment of Pancreas Cancer Presented at ASCO - The Role of Supportive Care - Specific Updates on the Treatment of Lymphoma Presented at ASCO - The Important Role of Clinical Trials: How Research Increases Treatment Options - Specific Updates on the Treatment of Leukemia Presented at ASCO - Communicating with Your Health Care Team: Key Questions to Ask - Specific Updates on the Treatment of Melanoma Presented at ASCO - Concluding Wrap-Up of Part II
- Overview of ASCO's 2024 Theme – “The Art and Science of Cancer Care from Comfort to Cure” - Specific Updates on the Treatment of Colorectal Cancer Presented at ASCO - Quality-of-Life Issues: Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Specific Updates on the Treatment of Pancreas Cancer Presented at ASCO - The Role of Supportive Care - Specific Updates on the Treatment of Lymphoma Presented at ASCO - The Important Role of Clinical Trials: How Research Increases Treatment Options - Specific Updates on the Treatment of Leukemia Presented at ASCO - Communicating with Your Health Care Team: Key Questions to Ask - Specific Updates on the Treatment of Melanoma Presented at ASCO - Concluding Wrap-Up of Part II
Triple Negative Breast Cancer CancerCare Connect Education Workshops
- 2024 American Society of Clinical Oncology (ASCO) Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions to Ask Our Panel of Experts
- 2024 American Society of Clinical Oncology (ASCO) Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions to Ask Our Panel of Experts
Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics: Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00) Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28) Treatment of HR-Positive, HER2-Negative Advanced Breast Cancer with a PI3K Mutation (29:46) Utility of Subsequent CDK4/6 Inhibitor After Disease Progression on Initial Therapy (34:57) Treatment of HER2-Low or HER2-Ultralow Metastatic Breast Cancer (40:59) Updated Data and Novel Strategies Involving Trastuzumab Deruxtecan for the Treatment of Advanced Breast Cancer (49:42) Oral Selective Estrogen Receptor Degraders for the Treatment of ER-Positive, HER2-Positive Breast Cancer (51:55) Novel Strategies Involving Antibody-Drug Conjugates and Immunotherapy for Triple-Negative Breast Cancer (58:12) CME information and select publications
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting.
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostASCO24/BreastCancer).
Ziad Bakouny, MD, MSc, and Nazli Dizman, MD, return to the show to discuss the progress made for International Medical Graduates (IMGs) within the American Society of Clinical Oncology (ASCO). Building on their previous conversation, they explore the origins of their initiatives at ASCO 2022, the goals for integrating IMGs into successful medical careers in the US, and the significant challenges posed by Visa constraints. Together, they expand on the unique hurdles faced by IMGs in oncology, how these compare across specialties, and the ongoing efforts to support IMGs. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
- Overview of ASCO's 2024 Theme – The Art and Science of Cancer from Comfort to Cure - Updates on the Treatment of Breast Cancer Presented at ASCO - Updates on the Treatment of Ovarian Cancer Presented at ASCO - The Role of Clinical Trials: How Research Increases Treatment Options - Updates on the Treatment of Prostate Cancer Presented at ASCO - Talking with Your Health Care Team about Your Treatment Choices - Updates on the Treatment of Brain Cancer Presented at ASCO - Quality-of-Life Concerns - Updates on the Treatment of Oral, Head and Neck Cancer Presented at ASCO - Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Updates on the Treatment of Sarcoma Presented at ASCO - Wrap-Up of Part I of ASCO 2024
- Overview of ASCO's 2024 Theme – The Art and Science of Cancer from Comfort to Cure - Updates on the Treatment of Breast Cancer Presented at ASCO - Updates on the Treatment of Ovarian Cancer Presented at ASCO - The Role of Clinical Trials: How Research Increases Treatment Options - Updates on the Treatment of Prostate Cancer Presented at ASCO - Talking with Your Health Care Team about Your Treatment Choices - Updates on the Treatment of Brain Cancer Presented at ASCO - Quality-of-Life Concerns - Updates on the Treatment of Oral, Head and Neck Cancer Presented at ASCO - Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Updates on the Treatment of Sarcoma Presented at ASCO - Wrap-Up of Part I of ASCO 2024
In this episode, Dr. Doug Blayney, oncologist, former President of the American Society of Clinical Oncology (ASCO), and the Chief Medical Officer of Manta Cares, discusses the latest advancements in breast cancer treatments presented at ASCO's 2024 Annual Meeting. He highlights the significant progress in antibody drug conjugates (ADCs), which are engineered to specifically target cancer cells, offering new hope in cancer treatment. The Manta Cares team also attended the ASCO conference, presenting an abstract for a personal treatment management tool designed to assist cancer patients and survivors (and their families!) in navigating their next steps – Manta Maps! For more information, visit our website here and join the list to request access to the digital platform this fall here. Key Highlights: 1. Advancements in breast cancer treatment were highlighted at the ASCO Annual Meeting this year, including alternatives to chemotherapy and the emergence of antibody drug conjugates (ADCs). 2. Checkpoint inhibitors help the immune system recognize and attack cancer cells by removing the "brakes" that prevent the immune system from targeting the cancer. 3. Personalized approaches to treatment based on patient age, co-morbidities, and cancer type, were highlighted, leading to more effective and tailored treatments. About our guest: Dr. Doug Blayney is an oncology physician who specializes in breast cancer. His research focuses on quality improvement in cancer care systems, new drug development, and patient experience improvement. At the American Society of Clinical Oncology (ASCO), he was founding Editor-in-Chief of its flagship practice journal, and as President, started the ASCO Quality Symposium and began planning for ASCO's CancerLinq. He was a founding member of the National Comprehensive Cancer Network (NCCN) Growth Factor Guideline panel, and is a past member of the U.S. Food and Drug Administration's Oncology Drugs Advisory Committee and the NCCN Board of Directors. Dr. Blayney leads the Manta Cares Scientific Advisory Board as the Chief Medical Officer. Key Moments: At 1:05 "As a doctor who treats breast cancer, I thought it was important that we have a lot of alternatives to chemotherapy. So even though some of the studies were portrayed as negative because they didn't improve overall survival, I think pushing out the time a patient gets chemotherapy and its associated toxicities is a major advance.” At 21:14 "We need better assays to predict who's going to respond to these ADCs (Antibody Drug Conjugates). We're learning that they're here to stay and they're a great benefit to many with breast cancer and other cancers." At 35:20 “It's thought that you and people without known cancer, develop one or two cancers a day, small little bitty ones and our body's immune system recognizes that as foreign and eats them up and the cancer doesn't grow and proliferate. One of the ways cancer grows, especially in adults, is immune escape. So somehow the brakes are put on the immune system at some point when that cancer develops. The IO checkpoint inhibitors are thought to work by taking off those brakes.” Visit the Manta Cares website Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions. --- Support this podcast: https://podcasters.spotify.com/pod/show/manta-cares/support
This installment of Oncology Data Advisor's Exploring Artificial Intelligence (AI) in Oncology series features a discussion recorded live at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting between Ranjana Devi, Vice President of Product Development, Oncology, at Qure.ai, and Fellows Forum member Dr. Waqas Haque. Check out the episode to hear more about: • Qure.ai's mission of making healthcare more accessible and equitable to patients worldwide through innovations in deep learning and AI • Current challenges in lung cancer screening and the capabilities of AI in addressing these gaps • Qure.ai's end-to-end AI-powered solutions for early lung cancer detection and care • The efficacy of these solutions and how they can be used in the clinic • The lung cancer portfolio that Qure.ai showcased at ASCO • Other innovations coming down the pipeline • And more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
Drs. Claudine Isaacs and Filipa Lynce discuss highlights of the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, with a focus on HER2+ breast cancer, including late-breaking abstracts such as DESTINY‑Breast06 and others.
Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologies and more. The Fierce team is always on the ground at the ASCO meeting, and this year, Fierce Biotech's Gabrielle Masson and Fierce Pharma's Angus Liu covered the event. In this week's episode of "The Top Line," they discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead's virtual reality Trodelvy ride. To learn more about the topics in this episode: Akeso, Summit's Keytruda win draws 'explosive' interest at ASCO. But what does Merck think? ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine ASCO: Cautious Big Pharmas double down on past wins—steering clear of radioligands and cell therapy See omnystudio.com/listener for privacy information.
A snub by an FDA advisory committee for an MDMA-psychotherapy combination is unlikely to read through to other psychedelic therapies in the pipeline. On the BioCentury This Week podcast, BioCentury's editors discuss the shortcomings of the Lykos Therapeutics product's clinical development program and why other psychedelics likely won't face the same hurdles. The editors also assess FDA's new platform technology designation and the first-in-human clinical trials described at this year's American Society of Clinical Oncology (ASCO) meeting. This week's podcast is sponsored by Nxera Pharma.00:01 - Sponsor Message: Nxera Pharma01:41 - Psychedelic Setback12:38 - FDA's Platform Play21:39 - ASCO Innovations
While there is undeniable hope for the future of cancer care, systemic barriers still impact access for many patients – particularly those in underserved communities. This session, originally recorded in front of a live audience at SXSW 2024, examines how increasing collaboration and partnerships among organizations that touch all aspects of the cancer journey and reach patients, providers and treatment centers, is critical to expanding access to optimal cancer care and making the goals of the “Cancer Moonshot” a reality. Hear from City of Hope, American Society of Clinical Oncology (ASCO), and American Cancer Society (ACS) about how they are approaching partnerships to create a future where every cancer patient has access to the care they need.